1. Home
  2. HPK vs ITRM Comparison

HPK vs ITRM Comparison

Compare HPK & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HPK
  • ITRM
  • Stock Information
  • Founded
  • HPK 2019
  • ITRM 2015
  • Country
  • HPK United States
  • ITRM Ireland
  • Employees
  • HPK N/A
  • ITRM N/A
  • Industry
  • HPK Oil & Gas Production
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • HPK Energy
  • ITRM Health Care
  • Exchange
  • HPK Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • HPK N/A
  • ITRM 35.6M
  • IPO Year
  • HPK N/A
  • ITRM 2018
  • Fundamental
  • Price
  • HPK $8.99
  • ITRM $1.03
  • Analyst Decision
  • HPK Sell
  • ITRM Strong Buy
  • Analyst Count
  • HPK 2
  • ITRM 2
  • Target Price
  • HPK $11.50
  • ITRM $7.00
  • AVG Volume (30 Days)
  • HPK 316.9K
  • ITRM 536.8K
  • Earning Date
  • HPK 05-12-2025
  • ITRM 05-13-2025
  • Dividend Yield
  • HPK 1.84%
  • ITRM N/A
  • EPS Growth
  • HPK N/A
  • ITRM N/A
  • EPS
  • HPK 0.67
  • ITRM N/A
  • Revenue
  • HPK $1,069,414,000.00
  • ITRM N/A
  • Revenue This Year
  • HPK N/A
  • ITRM N/A
  • Revenue Next Year
  • HPK N/A
  • ITRM $108.39
  • P/E Ratio
  • HPK $12.20
  • ITRM N/A
  • Revenue Growth
  • HPK N/A
  • ITRM N/A
  • 52 Week Low
  • HPK $7.82
  • ITRM $0.81
  • 52 Week High
  • HPK $17.48
  • ITRM $3.02
  • Technical
  • Relative Strength Index (RSI)
  • HPK 45.16
  • ITRM 44.07
  • Support Level
  • HPK $7.87
  • ITRM $0.88
  • Resistance Level
  • HPK $8.25
  • ITRM $1.14
  • Average True Range (ATR)
  • HPK 0.47
  • ITRM 0.10
  • MACD
  • HPK 0.11
  • ITRM -0.01
  • Stochastic Oscillator
  • HPK 49.64
  • ITRM 30.56

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: